ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pneumococcal 21-Valent Conjugate Vaccine

Also written as “V116”, “PCV21 vaccine” and “PCV21”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Anemia, Sickle Cell, led by 2 companies.

Drug pagePneumococcal 21-Valent Conjugate Vaccine: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 23, 202218 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only110 open or runningphase 3since May 23, 2022Nov 18, 2019none ahead
Sanofi77 open or runningphase 3since Oct 10, 2024Oct 10, 2024Dec 1, 2026phase 3 · NCT06838000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2024First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT06838000 · 1,268 enrolled · United States, Estonia, Poland and more
  2. Dec 11, 2024Phase 3 study in Pneumococcal ImmunizationNCT06736041 · 1,714 enrolled · United States, Australia, Honduras and more
  3. Feb 7, 20252 phase 3 studies in Pneumococcal ImmunizationNCT06824194, NCT06824181
  4. May 8, 2025Phase 3 study in Pneumococcal ImmunizationNCT06975878 · 1,092 enrolled · Belgium, Czechia, Estonia and more
  5. Nov 19, 2025Phase 3 study in Anemia, Sickle CellNCT07247188 · 100 planned · United States, Dominican Republic
  6. Jan 15, 2026Phase 3 study in Pneumococcal InfectionsNCT07348692 · 2,195 planned · United States, Honduras, Puerto Rico and more

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Pneumococcal InfectionsNCT06838000
  2. Jan 7, 2027Primary completion: phase 3 study in Anemia, Sickle CellNCT07247188
  3. May 17, 2027Primary completion: phase 3 study in Pneumococcal ImmunizationNCT06736041
  4. Jun 7, 2027Primary completion: phase 3 study in Pneumococcal InfectionsNCT07348692

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 21 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 21-Valent Conjugate Vaccine”name, by rule

Studies

All 7 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07348692Pneumococcal Infections · United States, Honduras, Puerto Rico and more3RecruitingJun 7, 20272,195
NCT07247188Anemia, Sickle Cell · United States, Dominican Republic3RecruitingJan 7, 2027100
NCT06975878Pneumococcal Immunization · Belgium, Czechia, Estonia and more3Active, not recruitingAug 25, 20271,092
NCT06824194Pneumococcal Immunization · United States, Honduras, Mexico and more3Active, not recruitingOct 22, 20272,360
NCT06824181Pneumococcal Immunization · United States, Chile, Mexico and more3Active, not recruitingSep 10, 2027580
NCT06736041Pneumococcal Immunization · United States, Australia, Honduras and more3Active, not recruitingMay 17, 20271,714
NCT06838000Pneumococcal Infections · United States, Estonia, Poland and more3Active, not recruitingDec 1, 20261,268

How it is read

Names in the registry

  • “V116”, 11 entries
  • “PCV21 vaccine”, 5 entries
  • “PCV21”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.